Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved]
Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and...
Main Authors: | Georgios Nikolakis, Katja Kreibich, Aristeidis Vaiopoulos, Katarzyna Kaleta, Joud Talas, Markus Becker, Christos C. Zouboulis |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2021-07-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/10-381/v2 |
Similar Items
-
Real-Life Experience of Secukinumab in Patients With Hidradenitis Suppurativa
by: F.J. Melgosa Ramos, et al.
Published: (2023-04-01) -
Autoinflammation in Syndromic Hidradenitis Suppurativa: The Role of AIM2
by: Chiara Moltrasio, et al.
Published: (2023-01-01) -
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023-01-01) -
Keratitis-ichthyosis-deafness syndrome and hidradenitis suppurativa
by: Lisa Travis, MD, et al.
Published: (2023-08-01) -
Sweet syndrome in a patient with Hidradenitis Suppurativa
by: Lakshay Jain, et al.
Published: (2020-04-01)